Skip to main content
Erschienen in: Pituitary 1/2010

01.03.2010

Immunohistochemistry of COUP-TFI: an adjuvant diagnostic tool for the identification of corticotroph microadenomas

verfasst von: Zachary M. Bush, Maria-Beatriz S. Lopes, Isa M. Hussaini, John A. Jane Jr., Edward R. Laws Jr., Mary Lee Vance

Erschienen in: Pituitary | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Cushing’s disease is caused by an ACTH-producing pituitary tumor, and accounts for 10–15% of pituitary tumors. The majority of corticotroph tumors are microadenomas (<10 mm), and accurate histologic identification of these tumors can be challenging because of their small size and the presence of nests of normal corticotroph cells in the anterior pituitary. Retinoic acid has been shown to inhibit ACTH production and induce apoptosis in corticotroph tumor cells. The expression of the orphan nuclear receptor COUP-TFI antagonizes retinoic acid signaling and has been shown to be expressed in normal corticotroph cells, but absent in corticotroph tumor cell lines. We analyzed 34 corticotroph tumor specimens by immunohistochemistry using a goat polyclonal IgG antibody with epitope mapping to the N-terminus of human COUP-TFI. Segments of normal pituitary in each of the 34 specimens demonstrate COUP-TFI immunoreactivity in normal corticotroph cells. Twenty-nine of 34 ACTH producing tumors were immunonegative for COUP-TFI. All of the tumors measuring less than 5 mm by preoperative MRI were COUP-TFI immunonegative. Two tumors, measuring 9 and 11 mm, showed consistent (>90%) expression of COUP-TFI, and three adenomas (5, 11, and 18 mm) showed heterogenous (20–80%) expression of COUP-TFI. Immunohistochemistry of COUP-TFI may be a useful adjuvant diagnostic tool in distinguishing corticotroph microadenomas from nests of normal corticotroph cells in the anterior pituitary. Furthermore, this study identifies two unique corticotroph tumor populations which differ in their expression of COUP-TFI, the presence of which occurs more frequently in macroadenomas.
Literatur
1.
Zurück zum Zitat Kovacs K (2001) Classification of pituitary adenomas. J Neurooncology 54:121–127CrossRef Kovacs K (2001) Classification of pituitary adenomas. J Neurooncology 54:121–127CrossRef
2.
Zurück zum Zitat Prezant TR, Melmed S (2002) Molecular pathogenesis of pituitary disorders. Curr Opin Endocrinol and Diabetes 9:61–78CrossRef Prezant TR, Melmed S (2002) Molecular pathogenesis of pituitary disorders. Curr Opin Endocrinol and Diabetes 9:61–78CrossRef
3.
Zurück zum Zitat Farrell WE, Clayton RN (2003) Epigenetic change in pituitary tumorigenesis. Endocr Relat Cancer 10:323–330CrossRefPubMed Farrell WE, Clayton RN (2003) Epigenetic change in pituitary tumorigenesis. Endocr Relat Cancer 10:323–330CrossRefPubMed
4.
Zurück zum Zitat Melmed S (2003) Mechanisms for pituitary tumorigenesis: the plastic pituitary. J Clin Invest 112:1603–1618PubMed Melmed S (2003) Mechanisms for pituitary tumorigenesis: the plastic pituitary. J Clin Invest 112:1603–1618PubMed
5.
Zurück zum Zitat Newell-Price J, Trainer P, Besser M, Grossman A (1998) The diagnosis and differential diagnosis of Cushing’s syndrome and Pseudo-Cushing’s states. Endocr Rev 19:647–672CrossRefPubMed Newell-Price J, Trainer P, Besser M, Grossman A (1998) The diagnosis and differential diagnosis of Cushing’s syndrome and Pseudo-Cushing’s states. Endocr Rev 19:647–672CrossRefPubMed
6.
Zurück zum Zitat Catargi B, Rigalleau V, Poussin A, Ronci-Chaix N, Bex V, Vergnot V et al (2003) Occult Cushing’s syndrome in Type-2 diabetes. J Clin Endocrinol Metab 88(12):5808–5813CrossRefPubMed Catargi B, Rigalleau V, Poussin A, Ronci-Chaix N, Bex V, Vergnot V et al (2003) Occult Cushing’s syndrome in Type-2 diabetes. J Clin Endocrinol Metab 88(12):5808–5813CrossRefPubMed
7.
Zurück zum Zitat Findling JW, Raff H (2006) Cushing’s Syndrome: important issues in diagnosis and management. J Clin Endocrinol Metab 91:3746–3753CrossRefPubMed Findling JW, Raff H (2006) Cushing’s Syndrome: important issues in diagnosis and management. J Clin Endocrinol Metab 91:3746–3753CrossRefPubMed
8.
Zurück zum Zitat Newell-Price J, Bertagna X, Grossman AB, Nieman LK (2006) Cushing’s syndrome. The Lancet 367(9522):1605–1617CrossRef Newell-Price J, Bertagna X, Grossman AB, Nieman LK (2006) Cushing’s syndrome. The Lancet 367(9522):1605–1617CrossRef
9.
Zurück zum Zitat Tran HA, Petrovsky N (2006) Difficulties in excluding Cushing syndrome in obese subjects. The Endocrinologist 16:15–19CrossRef Tran HA, Petrovsky N (2006) Difficulties in excluding Cushing syndrome in obese subjects. The Endocrinologist 16:15–19CrossRef
10.
Zurück zum Zitat Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP et al (2003) Diagnosis and complications of Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 88:5593–5602CrossRefPubMed Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP et al (2003) Diagnosis and complications of Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 88:5593–5602CrossRefPubMed
11.
Zurück zum Zitat Raff H, Raff JL, Findling JW (1998) Late-night salivary cortisol as a screening test for Cushing’s syndrome. J Clin Endocrinol Metab 83:2681–2686CrossRefPubMed Raff H, Raff JL, Findling JW (1998) Late-night salivary cortisol as a screening test for Cushing’s syndrome. J Clin Endocrinol Metab 83:2681–2686CrossRefPubMed
12.
Zurück zum Zitat Papanicolaou DA, Mullen N, Kyrou I, Nieman LK (2002) Nighttime salivary cortisol: a useful test for the diagnosis of Cushing’s syndrome. J Clin Endocrinol Metab 87:4515–4521CrossRefPubMed Papanicolaou DA, Mullen N, Kyrou I, Nieman LK (2002) Nighttime salivary cortisol: a useful test for the diagnosis of Cushing’s syndrome. J Clin Endocrinol Metab 87:4515–4521CrossRefPubMed
13.
Zurück zum Zitat Martinelli CE, Sader SL, Oliveira EB, Daneluzzi JC, Moreira AC (1998) Salivary cortisol for screening of Cushing’s syndrome in children. Clin Endocrinol 51:67–71CrossRef Martinelli CE, Sader SL, Oliveira EB, Daneluzzi JC, Moreira AC (1998) Salivary cortisol for screening of Cushing’s syndrome in children. Clin Endocrinol 51:67–71CrossRef
14.
Zurück zum Zitat Bochicchio D, Losa M, Buchfelder M (1995) Factors influencing the immediate and late outcome of Cushing’s disease treated by transsphenoidal surgery: a retrospective study by the European Cushing’s disease survey group. J Clin Endocrinol Metab 80:3114–3120CrossRefPubMed Bochicchio D, Losa M, Buchfelder M (1995) Factors influencing the immediate and late outcome of Cushing’s disease treated by transsphenoidal surgery: a retrospective study by the European Cushing’s disease survey group. J Clin Endocrinol Metab 80:3114–3120CrossRefPubMed
15.
Zurück zum Zitat Semple PL, Vance ML, Findling JW, Laws ER (2000) Transsphenoidal Surgery for Cushing’s disease: outcome in patients with a normal magnetic resonance imaging scan. Neurosurgery 46:553–559CrossRef Semple PL, Vance ML, Findling JW, Laws ER (2000) Transsphenoidal Surgery for Cushing’s disease: outcome in patients with a normal magnetic resonance imaging scan. Neurosurgery 46:553–559CrossRef
16.
Zurück zum Zitat Invitti C, Giraldi FP, De Martin M, Cavagnini F (1999) Diagnosis and management of Cushing’s syndrome: results of an Italian multicentre study. J Clin Endocrinol Metab 84:440–448CrossRefPubMed Invitti C, Giraldi FP, De Martin M, Cavagnini F (1999) Diagnosis and management of Cushing’s syndrome: results of an Italian multicentre study. J Clin Endocrinol Metab 84:440–448CrossRefPubMed
17.
Zurück zum Zitat Jane JA, Laws ER (2001) The surgical management of pituitary adenomas in a series of 3, 093 patients. J Am Coll Surg 193:650–659CrossRef Jane JA, Laws ER (2001) The surgical management of pituitary adenomas in a series of 3, 093 patients. J Am Coll Surg 193:650–659CrossRef
18.
Zurück zum Zitat Patil CG, Prevedello DM, Lad SP, Vance ML, Thorner MO, Katznelson L et al (2008) Late recurrences of Cushing’s disease after initial successful transsphenoidal surgery. J Clin Endocrinol Metab 93:358–362CrossRefPubMed Patil CG, Prevedello DM, Lad SP, Vance ML, Thorner MO, Katznelson L et al (2008) Late recurrences of Cushing’s disease after initial successful transsphenoidal surgery. J Clin Endocrinol Metab 93:358–362CrossRefPubMed
19.
Zurück zum Zitat Friedman RB, Oldfield EH, Nieman LK, Chrousos GP, Doppman JL, Cutler GB Jr et al (1989) Repeat transsphenoidal surgery for Cushing’s disease. J Neurosurg 71:520–527CrossRefPubMed Friedman RB, Oldfield EH, Nieman LK, Chrousos GP, Doppman JL, Cutler GB Jr et al (1989) Repeat transsphenoidal surgery for Cushing’s disease. J Neurosurg 71:520–527CrossRefPubMed
20.
Zurück zum Zitat Sheehan J, Steiner L, Laws ER (2005) Pituitary adenomas: is Gamma Knife® radiosurgery safe? Nat Clin Pract Endocrinol Metab 1:1–3CrossRef Sheehan J, Steiner L, Laws ER (2005) Pituitary adenomas: is Gamma Knife® radiosurgery safe? Nat Clin Pract Endocrinol Metab 1:1–3CrossRef
21.
Zurück zum Zitat Engelhardt D, Weber MM (1994) Therapy of Cushing’s syndrome with steroid biosynthesis inhibitors 106. J Steroid Biochem Mol Biol 49:261–267CrossRefPubMed Engelhardt D, Weber MM (1994) Therapy of Cushing’s syndrome with steroid biosynthesis inhibitors 106. J Steroid Biochem Mol Biol 49:261–267CrossRefPubMed
22.
Zurück zum Zitat Sonino N, Boscaro M (1999) Medical therapy for Cushing’s disease. Endocrinol Metab Clin North Am 28:211–222CrossRefPubMed Sonino N, Boscaro M (1999) Medical therapy for Cushing’s disease. Endocrinol Metab Clin North Am 28:211–222CrossRefPubMed
23.
Zurück zum Zitat Naoumenko J, Feigin I (1974) A simple silver solution for staining reticulin. Biotech Histochem 49:153–155CrossRef Naoumenko J, Feigin I (1974) A simple silver solution for staining reticulin. Biotech Histochem 49:153–155CrossRef
24.
Zurück zum Zitat Paez-Pereda M, Kovalovsky D, Hopfner U, Theodoropoulou M, Pagotto U, Uhl E et al (2001) Retinoic acid prevents experimental Cushing syndrome. J Clin Invest 108:1123–1131PubMed Paez-Pereda M, Kovalovsky D, Hopfner U, Theodoropoulou M, Pagotto U, Uhl E et al (2001) Retinoic acid prevents experimental Cushing syndrome. J Clin Invest 108:1123–1131PubMed
25.
Zurück zum Zitat Hsu SM, Raine L, Fanger H (1981) The use of antiavidin antibody and avidin-biotin-peroxidase complex in immunoperoxidase techniques. Am J Clin Pathol 75:816–821PubMed Hsu SM, Raine L, Fanger H (1981) The use of antiavidin antibody and avidin-biotin-peroxidase complex in immunoperoxidase techniques. Am J Clin Pathol 75:816–821PubMed
26.
Zurück zum Zitat Norton AJ, Jordan S, Yeomans P (1994) Brief, high-temperature heat denaturation (pressure cooking): a simple and effective method of antigen retrieval for routinely processed tissues. J Pathol 173:371–379CrossRefPubMed Norton AJ, Jordan S, Yeomans P (1994) Brief, high-temperature heat denaturation (pressure cooking): a simple and effective method of antigen retrieval for routinely processed tissues. J Pathol 173:371–379CrossRefPubMed
27.
Zurück zum Zitat Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD et al (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150:76–85CrossRefPubMed Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD et al (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150:76–85CrossRefPubMed
28.
Zurück zum Zitat Pereira FA, Tsai MJ, Tsai SY (2000) COUP-TF orphan nuclear receptors in development and differentiation. Cell Mol Life Sci 57:1388–1398CrossRefPubMed Pereira FA, Tsai MJ, Tsai SY (2000) COUP-TF orphan nuclear receptors in development and differentiation. Cell Mol Life Sci 57:1388–1398CrossRefPubMed
29.
Zurück zum Zitat Kliewer SA, Umesono K, Heyman RA, Mangelsdorf DJ, Dyck JA, Evans RM (1992) Retinoid X receptor-COUP-TF interactions modulate retinoic acid signaling. Proc Natl Acad Sci 89:1448–1452CrossRefPubMed Kliewer SA, Umesono K, Heyman RA, Mangelsdorf DJ, Dyck JA, Evans RM (1992) Retinoid X receptor-COUP-TF interactions modulate retinoic acid signaling. Proc Natl Acad Sci 89:1448–1452CrossRefPubMed
30.
Zurück zum Zitat Ben Shushan E, Sharir H, Pikarsky E, Bergman Y (1995) A dynamic balance between ARP-1/COUP-TFII, EAR-3/COUP-TFI, and retinoic acid receptor:retinoid X receptor heterodimers regulates Oct-3/4 expression in embryonal carcinoma cells. Mol Cell Biol 15:1034–1048PubMed Ben Shushan E, Sharir H, Pikarsky E, Bergman Y (1995) A dynamic balance between ARP-1/COUP-TFII, EAR-3/COUP-TFI, and retinoic acid receptor:retinoid X receptor heterodimers regulates Oct-3/4 expression in embryonal carcinoma cells. Mol Cell Biol 15:1034–1048PubMed
31.
32.
Zurück zum Zitat Kang HJ, Song MR, Lee SK, Shin EC, Choi YH, Kim SJ et al (2000) Retinoic acid and its receptors repress the expression and transactivation functions of Nur77: a possible mechanism for the inhibition of apoptosis by retinoic acid. Exp Cell Res 256:545–554CrossRefPubMed Kang HJ, Song MR, Lee SK, Shin EC, Choi YH, Kim SJ et al (2000) Retinoic acid and its receptors repress the expression and transactivation functions of Nur77: a possible mechanism for the inhibition of apoptosis by retinoic acid. Exp Cell Res 256:545–554CrossRefPubMed
33.
Zurück zum Zitat Castillo V, Giacomini D, Paez-Pereda M, Stalla J, Labeur M, Theodoropoulou M et al (2006) Retinoic acid as a novel medical therapy for Cushing’s disease in dogs. Endocrinology 147:4438–4444CrossRefPubMed Castillo V, Giacomini D, Paez-Pereda M, Stalla J, Labeur M, Theodoropoulou M et al (2006) Retinoic acid as a novel medical therapy for Cushing’s disease in dogs. Endocrinology 147:4438–4444CrossRefPubMed
34.
Zurück zum Zitat Dahia PLM, Grossman AB (1999) The molecular pathogenesis of corticotroph tumors. Endocr Rev 20:136–155CrossRefPubMed Dahia PLM, Grossman AB (1999) The molecular pathogenesis of corticotroph tumors. Endocr Rev 20:136–155CrossRefPubMed
35.
Zurück zum Zitat Drouin J, Bilodeau S, Vallette S (2007) Of old and new diseases: genetics of pituitary ACTH excess (Cushing) and deficiency. Clin Genet 72:175–182CrossRefPubMed Drouin J, Bilodeau S, Vallette S (2007) Of old and new diseases: genetics of pituitary ACTH excess (Cushing) and deficiency. Clin Genet 72:175–182CrossRefPubMed
36.
Zurück zum Zitat Herman V, Fagin J, Gonsky R, Kovacs K, Melmed S (1990) Clonal origin of pituitary adenomas. J Clin Endocrinol Metab 71:1427–1433CrossRefPubMed Herman V, Fagin J, Gonsky R, Kovacs K, Melmed S (1990) Clonal origin of pituitary adenomas. J Clin Endocrinol Metab 71:1427–1433CrossRefPubMed
37.
Zurück zum Zitat Allenby G, Bocquel M, Saunders M, Kazmer S, Speck J, Rosenberger M et al (1993) Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci 90:30–34CrossRefPubMed Allenby G, Bocquel M, Saunders M, Kazmer S, Speck J, Rosenberger M et al (1993) Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci 90:30–34CrossRefPubMed
Metadaten
Titel
Immunohistochemistry of COUP-TFI: an adjuvant diagnostic tool for the identification of corticotroph microadenomas
verfasst von
Zachary M. Bush
Maria-Beatriz S. Lopes
Isa M. Hussaini
John A. Jane Jr.
Edward R. Laws Jr.
Mary Lee Vance
Publikationsdatum
01.03.2010
Verlag
Springer US
Erschienen in
Pituitary / Ausgabe 1/2010
Print ISSN: 1386-341X
Elektronische ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-009-0189-8

Weitere Artikel der Ausgabe 1/2010

Pituitary 1/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.